Thermo Fisher Scientific Ataxin 1 Monoclonal Antibody (2F5)

Thermo Fisher Scientific Ataxin 1 Monoclonal Antibody (2F5)

Applications and Tested Dilution

Product Specifications

Product Specific Information

MA5-15735 targets ATXN1 in indirect ELISA, FACS, IF, IHC, and WB applications and shows reactivity with human samples.
The immunogen is a purified recombinant fragment of human ATXN1 expressed in E. coli.
MA5-15735 detects ATXN1 with a predicted molecular weight of approximately 87 kDa.

Target Information

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem, and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I–III.
ADCAI is genetically heterogeneous, with five genetic loci designated spinocerebellar ataxia (SCA) 1, 2, 3, 4, and 6, each assigned to different chromosomes. ADCAII, which presents with retinal degeneration (SCA7), and ADCAIII, referred to as the ‘pure’ cerebellar syndrome (SCA5), are more homogeneous disorders.
Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by expansion of CAG repeats, producing elongated polyglutamine tracts in the corresponding proteins. The expanded repeats are variable and unstable, usually increasing in size across generations.
The function of ataxins remains unknown. The ATXN1 locus is mapped to chromosome 6; the diseased allele contains 41–81 CAG repeats compared to 6–39 in the normal allele and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been identified for this gene.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.